A Phase 3, Multicenter, Randomized, Efficacy Assessor-Blinded study of Risankizumab Compared to Ustekinumab for the Treatment of Adult Subjects with Moderate to Severe Crohn’sDisease who have failed anti-TNF therapy

Project: Research

Project Details

Project Description

Effective start/end date23/02/2125/02/26


  • clinical trial
  • treatment safety
  • treatment efficacy
  • phase 3 study
  • Crohn's disease